Stock Price Quote

SEQUENT SCIENTIFIC LTD.

NSE : SEQUENTBSE : 512529ISIN CODE : INE807F01027Industry : Pharmaceuticals & DrugsHouse : Sequent
BSE116.350.2 (+0.17 %)
PREV CLOSE ( ) 116.15
OPEN PRICE ( ) 116.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8536
TODAY'S LOW / HIGH ( )116.00 117.80
52 WK LOW / HIGH ( )70.15 155.45
NSE116.550.35 (+0.3 %)
PREV CLOSE( ) 116.20
OPEN PRICE ( ) 116.35
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 116.55 (110)
VOLUME 105236
TODAY'S LOW / HIGH( ) 115.75 117.60
52 WK LOW / HIGH ( )70.6 155.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-06 1985
Management Info
Kamal K Sharma - Chairman Rajaram Narayanan - Managing Director
Registered Office

Address 301, ' Dosti Pinnacle',3rd Floor, Plot No. E7,Road No. 22, Wagle Indl. Estate,
Thane,
Maharashtra-400604

Phone 022 4111 4777

Email investorrelations@sequent.in

Website www.sequent.in

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

13May Sequent Scientific informs about analy
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
18Apr Announcement under Regulation 30 (LOD
Allotment of Equity Shares under Sequent Scientific Limited Employee Sto..
04Apr Sequent Scientific informs about resig
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
08Feb Sequent Scientific to sell plot locate
Sequent Scientific has executed Deed of assignment on February 08, 2024,..
13Nov Sequent Scientific informs about trans
Pursuant to Regulation 30(6) of the Securities and Exchange Board of Ind..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit37.636.21999999999984
Gross Profit 41 -2.39000000000016
Operating Profit 72.34193.16
Net Sales 367.711685.18

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26643.70 (0.58%)
M.Cap ( in Cr)56616.00
Pfizer (BSE)
peergroup  4473.85 (1.59%)
M.Cap ( in Cr)20466.85
Glaxosmithkline Phar (BSE)
peergroup  2355.75 (2.80%)
M.Cap ( in Cr)39907.83
Concord Biotech (BSE)
peergroup  1494.85 (4.43%)
M.Cap ( in Cr)15638.55
Zydus Lifesciences (BSE)
peergroup  1104.45 (5.00%)
M.Cap ( in Cr)111133.51

Shareholding Pattern

PROMOTERS 52.79%
MUTUAL FUNDS/UTI 5.16%
NON-INSTITUTION 33.46%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Sequent Scientific Ltd.

Sequent Scientific Ltd. was incorporated in the year 1985. Its today's share price is 116.35. Its current market capitalisation stands at Rs 2902.71 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2251.81 Cr and Total Income of Rs.2509.7 Cr. The company's management includes Vedprakash Ragate, Phillip Trott, Hari Babu Bodepudi, Gregory John Andrews, Neeraj Bharadwaj, Fabian Kausche, Rajaram Narayanan, Kausalya Santhanam, Milind Sarwate, Kamal K Sharma.

It is listed on the BSE with a BSE Code of 512529 , NSE with an NSE Symbol of SEQUENT and ISIN of INE807F01027. It's Registered office is at 301, ' Dosti Pinnacle',3rd Floor, Plot No. E7,Road No. 22, Wagle Indl. EstateThane-400604, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.